Oddway International is the leading Exporters of number of brands of Erythropoietin Injections manufactured by Indian and multinational pharmaceutical countries. Buy original Erythropoietin Injections at wholesale price , We Export Erythropoietin injection(recombinant human Erythropoietin) worlwide including ,South Korea ,India ,Singapore ,United States ,Australia ,Philippines ,Malaysia ,Canada ,Taiwan ,United Kingdom ,China Etc Also Order Bulk Medication email@example.com
Erythropoietin syringe is a glycoprotein hormone produced by the kidney. It is synthesized in response to hypoxia. In anaemia, renal secretion of erythropoietin increases rapidly. It is prepared by DNA recombinant technology. Erythropoietin syringe acts on the most primitive precursors or progenitors of erythrocytes by acting on the cell membrane receptors. Erythropoietin stimulates erythrocytic process as well as their maturation and differentiation.
Erythropoietin injections is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture. It is used in treating anaemia resulting from chronic kidney disease and myelodysplasia, from the treatment of cancer (chemotherapy and radiation), and from other critical illnesses (heart failure).In patients that require dialysis (have stage 5 chronic kidney disease(CKD)), iron should be given with erythropoietin. Dialysis patients in the US are most often given Epogen; outside of the US other brands of epoetin may be used.
Outside of people on dialysis, erythropoietin is used most commonly to treat anemia in people with chronic kidney disease that are not on dialysis (those in stage 3 or 4 CKD and those living with a kidney transplant). There are two types of erythropoietin (and three brands) for people with anemia due to chronic kidney disease (not on dialysis):
In a recent randomized controlled trial,erythropoietin was shown to not change the number of blood transfusions required by critically ill patients. A surprising finding in this study is that a small mortality benefit in patients receiving erythropoietin. This result was statistically significant after 29 days but not at 140 days. This mortality difference was most marked in patients admitted to the ICU for trauma. The authors speculate several hypotheses of potential etiologies for reduced mortality, but, given the known increase in thrombosis and increase benefit in trauma patients as well as marginal nonsignificant benefit (adjusted hazard ratio of 0.9) in surgery patients, one might speculate that some of the benefit might be secondary to the procoagulant effect of erythropoetin. Regardless, this study suggests further research may be necessary to see which critical care patients, if anyone, might benefit from administration of erythropoeitin. Any benefit of erythropoetin must be weighed against the 50% increase in thrombosis, which has been well substantiated by numerous trials.